{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:41:06Z","timestamp":1794030066208,"version":"4.8.0"},"reference-count":80,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,11,7]]},"abstract":"\n Importance<\/jats:title>\n Alcohol use disorder affects more than 28.3 million people in the United States and is associated with increased rates of morbidity and mortality.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare efficacy and comparative efficacy of therapies for alcohol use disorder.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, the Cochrane Library, the Cochrane Central Trials Registry, PsycINFO, CINAHL, and EMBASE were searched from November 2012 to September 9, 2022 Literature was subsequently systematically monitored to identify relevant articles up to August 14, 2023, and the PubMed search was updated on August 14, 2023.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n For efficacy outcomes, randomized clinical trials of at least 12 weeks\u2019 duration were included. For adverse effects, randomized clinical trials and prospective cohort studies that compared drug therapies and reported health outcomes or harms were included.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Two reviewers evaluated each study, assessed risk of bias, and graded strength of evidence. Meta-analyses used random-effects models. Numbers needed to treat were calculated for medications with at least moderate strength of evidence for benefit.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was alcohol consumption. Secondary outcomes were motor vehicle crashes, injuries, quality of life, function, mortality, and harms.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Data from 118 clinical trials and 20\u202f976 participants were included. The numbers needed to treat to prevent 1 person from returning to any drinking were 11 (95% CI, 1-32) for acamprosate and 18 (95% CI, 4-32) for oral naltrexone at a dose of 50 mg\/d. Compared with placebo, oral naltrexone (50 mg\/d) was associated with lower rates of return to heavy drinking, with a number needed to treat of 11 (95% CI, 5-41). Injectable naltrexone was associated with fewer drinking days over the 30-day treatment period (weighted mean difference, \u22124.99 days; 95% CI, \u22129.49 to \u22120.49 days) Adverse effects included higher gastrointestinal distress for acamprosate (diarrhea: risk ratio, 1.58; 95% CI, 1.27-1.97) and naltrexone (nausea: risk ratio, 1.73; 95% CI, 1.51-1.98; vomiting: risk ratio, 1.53; 95% CI, 1.23-1.91) compared with placebo.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In conjunction with psychosocial interventions, these findings support the use of oral naltrexone at 50 mg\/d and acamprosate as first-line pharmacotherapies for alcohol use disorder.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.19761","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T11:41:39Z","timestamp":1699357299000},"page":"1653","source":"Crossref","is-referenced-by-count":318,"title":["Pharmacotherapy for Alcohol Use Disorder"],"prefix":"10.1001","volume":"330","author":[{"given":"Melissa","family":"McPheeters","sequence":"first","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-Based Practice Center, Chapel Hill"},{"name":"RTI International, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Riley","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-Based Practice Center, Chapel Hill"},{"name":"Department of Internal Medicine, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-Based Practice Center, Chapel Hill"},{"name":"RTI International, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Voisin","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-Based Practice Center, Chapel Hill"},{"name":"Department of Internal Medicine, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Kuznacic","sequence":"additional","affiliation":[{"name":"College of Pharmacy, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory P.","family":"Coffey","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Edlund","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiy","family":"Bobashev","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Jonas","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-Based Practice Center, Chapel Hill"},{"name":"Department of Internal Medicine, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"18","key":"joi230114r6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"joi230114r7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS: Peer Review of Electronic Search Strategies: 2015 guideline statement.","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"joi230114r10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"joi230114r11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jclinepi.2009.03.009","article-title":"Grading the strength of a body of evidence when comparing medical interventions\u2014Agency for Healthcare Research and Quality and the Effective Health-Care Program.","volume":"63","author":"Owens","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"joi230114r13","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.v21:11","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7414","key":"joi230114r14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"joi230114r15","first-page":"85","article-title":"A double blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence.","volume":"5","author":"Ahmadi","year":"2002","journal-title":"Ger J Psychiatry"},{"issue":"4","key":"joi230114r17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/01.jcp.0000172071.81258.04","article-title":"Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.","volume":"25","author":"Anton","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"joi230114r18","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","article-title":"Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.","volume":"156","author":"Anton","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"17","key":"joi230114r19","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"joi230114r20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/01.ALC.0000075548.83053.A9","article-title":"A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence.","volume":"27","author":"Balldin","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"joi230114r21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.15288\/jsa.2004.65.136","article-title":"Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting.","volume":"65","author":"Baltieri","year":"2004","journal-title":"J Stud Alcohol"},{"issue":"12","key":"joi230114r22","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1111\/add.2008.103.issue-12","article-title":"Comparing topiramate with naltrexone in the treatment of alcohol dependence.","volume":"103","author":"Baltieri","year":"2008","journal-title":"Addiction"},{"issue":"4","key":"joi230114r23","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/acer.2013.37.issue-4","article-title":"Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.","volume":"37","author":"Berger","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"joi230114r24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/acer.1998.22.issue-3","article-title":"Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.","volume":"22","author":"Besson","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"joi230114r25","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1111\/acer.2009.33.issue-11","article-title":"A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence.","volume":"33","author":"Brown","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"joi230114r26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"joi230114r27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","article-title":"United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol.","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol"},{"issue":"11","key":"joi230114r28","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism: a Veterans Administration Cooperative Study.","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"issue":"6","key":"joi230114r29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.7326\/0003-4819-90-6-901","article-title":"Disulfiram for the treatment of alcoholism: an evaluation in 128 men.","volume":"90","author":"Fuller","year":"1979","journal-title":"Ann Intern Med"},{"issue":"13","key":"joi230114r30","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"joi230114r31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/00004714-200212000-00009","article-title":"Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.","volume":"22","author":"Gastpar","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"joi230114r32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000259166","article-title":"Acamprosate and prevention of relapse in alcoholics: results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg.","volume":"3","author":"Geerlings","year":"1997","journal-title":"Eur Addict Res"},{"issue":"5","key":"joi230114r33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/alcalc\/36.5.413","article-title":"Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain.","volume":"36","author":"Gual","year":"2001","journal-title":"Alcohol Alcohol"},{"issue":"9","key":"joi230114r34","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/acer.2002.26.issue-9","article-title":"A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial.","volume":"26","author":"Guardia","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"joi230114r35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4088\/JCP.13m08940","article-title":"Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study).","volume":"76","author":"Higuchi","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"joi230114r36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/13556210500223504","article-title":"A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan.","volume":"10","author":"Huang","year":"2005","journal-title":"Addict Biol"},{"issue":"1","key":"joi230114r37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"joi230114r38","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1097\/01.ALC.0000145688.30448.2C","article-title":"Effectiveness of naltrexone in a community treatment program.","volume":"28","author":"Killeen","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"joi230114r39","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","article-title":"Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.","volume":"28","author":"Kranzler","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"issue":"24","key":"joi230114r40","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Naltrexone in the treatment of alcohol dependence.","volume":"345","author":"Krystal","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"joi230114r41","doi-asserted-by":"publisher","first-page":"530","DOI":"10.5694\/mja2.2002.176.issue-11","article-title":"Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting.","volume":"176","author":"Latt","year":"2002","journal-title":"Med J Aust"},{"issue":"2","key":"joi230114r42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/09595230120058579","article-title":"Naltrexone in the treatment of male alcoholics\u2014an effectiveness study in Singapore.","volume":"20","author":"Lee","year":"2001","journal-title":"Drug Alcohol Rev"},{"issue":"8436","key":"joi230114r43","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(85)91615-0","article-title":"Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.","volume":"1","author":"Lhuintre","year":"1985","journal-title":"Lancet"},{"issue":"6","key":"joi230114r44","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/oxfordjournals.alcalc.a045057","article-title":"Acamprosate appears to decrease alcohol intake in weaned alcoholics.","volume":"25","author":"Lhuintre","year":"1990","journal-title":"Alcohol Alcohol"},{"issue":"6","key":"joi230114r45","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/adb.2013.18.issue-6","article-title":"Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.","volume":"18","author":"Mann","year":"2013","journal-title":"Addict Biol"},{"issue":"5","key":"joi230114r46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jpsychires.2006.02.002","article-title":"Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.","volume":"40","author":"Mason","year":"2006","journal-title":"J Psychiatr Res"},{"issue":"11","key":"joi230114r47","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/acer.2001.25.issue-11","article-title":"Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.","volume":"25","author":"Monti","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"issue":"10","key":"joi230114r48","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1111\/add.2006.101.issue-10","article-title":"Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial.","volume":"101","author":"Morley","year":"2006","journal-title":"Addiction"},{"issue":"11","key":"joi230114r49","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1046\/j.1360-0443.2001.961115654.x","article-title":"Naltrexone for alcohol dependence: a randomized controlled trial.","volume":"96","author":"Morris","year":"2001","journal-title":"Addiction"},{"issue":"11","key":"joi230114r50","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study.","volume":"49","author":"O\u2019Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"joi230114r51","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/acer.2008.32.issue-7","article-title":"Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.","volume":"32","author":"O\u2019Malley","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"joi230114r52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/acer.2007.31.issue-4","article-title":"Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.","volume":"31","author":"O\u2019Malley","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"joi230114r53","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/acer.2008.32.issue-7","article-title":"A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.","volume":"32","author":"Oslin","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"joi230114r54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00019442-199700540-00007","article-title":"Naltrexone as an adjunctive treatment for older patients with alcohol dependence.","volume":"5","author":"Oslin","year":"1997","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"joi230114r55","first-page":"239","article-title":"Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol.","volume":"30","author":"Paille","year":"1995","journal-title":"Alcohol Alcohol"},{"key":"joi230114r57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1192\/bjp.171.1.73","article-title":"Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study.","volume":"171","author":"Pelc","year":"1997","journal-title":"Br J Psychiatry"},{"issue":"10","key":"joi230114r58","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.","volume":"57","author":"Petrakis","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"6","key":"joi230114r59","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","article-title":"A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.","volume":"167","author":"Pettinati","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"11","key":"joi230114r60","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/j.1360-0443.1997.tb02873.x","article-title":"Acamprosate treatment in a long-term community-based alcohol rehabilitation programme.","volume":"92","author":"Poldrugo","year":"1997","journal-title":"Addiction"},{"issue":"8","key":"joi230114r61","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/archpsyc.1996.01830080023006","article-title":"Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence.","volume":"53","author":"Sass","year":"1996","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"joi230114r62","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/alcalc\/35.2.202","article-title":"Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study.","volume":"35","author":"Tempesta","year":"2000","journal-title":"Alcohol Alcohol"},{"key":"joi230114r63","first-page":"39","article-title":"Naltrexone in the treatment of alcoholism: predicting response to naltrexone.","volume":"56","author":"Volpicelli","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"joi230114r64","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","article-title":"Naltrexone and alcohol dependence: role of subject compliance.","volume":"54","author":"Volpicelli","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"9013","key":"joi230114r65","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S0140-6736(96)91682-7","article-title":"Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.","volume":"347","author":"Whitworth","year":"1996","journal-title":"Lancet"},{"issue":"2-3","key":"joi230114r66","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.drugalcdep.2011.05.001","article-title":"The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial.","volume":"118","author":"W\u00f6lwer","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"joi230114r67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0005-7916(82)90050-7","article-title":"Alcoholism treatment by disulfiram and community reinforcement therapy.","volume":"13","author":"Azrin","year":"1982","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"5","key":"joi230114r68","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0005-7967(76)90021-8","article-title":"Improvements in the community-reinforcement approach to alcoholism.","volume":"14","author":"Azrin","year":"1976","journal-title":"Behav Res Ther"},{"issue":"3","key":"joi230114r69","doi-asserted-by":"publisher","first-page":"342","DOI":"10.7326\/0003-4819-89-3-342","article-title":"A behavioral treatment of alcoholic methadone patients.","volume":"89","author":"Liebson","year":"1978","journal-title":"Ann Intern Med"},{"issue":"6","key":"joi230114r70","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/archpsyc.1973.01750360034004","article-title":"Disulfiram maintenance in outpatient treatment of alcoholism.","volume":"28","author":"Gerrein","year":"1973","journal-title":"Arch Gen Psychiatry"},{"issue":"13","key":"joi230114r71","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.2014.10152","article-title":"Medications for alcohol use disorders.","volume":"312","author":"Saitz","year":"2014","journal-title":"JAMA"},{"issue":"13","key":"joi230114r72","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1001\/jama.2014.10170","article-title":"Medications for alcohol use disorders\u2014reply.","volume":"312","author":"Jonas","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"joi230114r73","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ypmed.2003.11.027","article-title":"A meta-analysis of alcohol consumption and the risk of 15 diseases.","volume":"38","author":"Corrao","year":"2004","journal-title":"Prev Med"},{"issue":"9662","key":"joi230114r74","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","article-title":"Alcohol-use disorders.","volume":"373","author":"Schuckit","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"joi230114r75","doi-asserted-by":"publisher","first-page":"535","DOI":"10.15288\/jsad.2008.69.535","article-title":"Alcohol-attributable fraction for injury in the U.S. general population: data from the 2005 National Alcohol Survey.","volume":"69","author":"Cherpitel","year":"2008","journal-title":"J Stud Alcohol Drugs"},{"issue":"3","key":"joi230114r76","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/01.jcp.0000084030.22282.6d","article-title":"Targeted naltrexone for early problem drinkers.","volume":"23","author":"Kranzler","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"joi230114r77","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/acer.v43.8","article-title":"Reduction in drinking was associated with improved clinical outcomes in women with HIV infection and unhealthy alcohol use: results from a randomized clinical trial of oral naltrexone versus placebo.","volume":"43","author":"Cook","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"joi230114r78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10461-018-2241-z","article-title":"Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: a randomized-controlled trial.","volume":"23","author":"Edelman","year":"2019","journal-title":"AIDS Behav"},{"issue":"5","key":"joi230114r79","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2013.8268","article-title":"Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial.","volume":"310","author":"Foa","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"joi230114r80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/alcalc\/agm136","article-title":"A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence.","volume":"43","author":"Laaksonen","year":"2008","journal-title":"Alcohol Alcohol"},{"key":"joi230114r12","volume-title":"Methods for Meta-Analysis in Medical Research","author":"Sutton","year":"2000"},{"key":"joi230114r56","volume-title":"Novel Pharmacological Interventions for Alcoholism","author":"Pelc","year":"1992"},{"key":"joi230114r1","unstructured":"Centers for Disease Control and Prevention. Deaths from excessive alcohol use in the United States. Accessed January 23, 2023, https:\/\/www.cdc.gov\/alcohol\/features\/excessive-alcohol-deaths.html"},{"key":"joi230114r2","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2020 National Survey on Drug Use and Health. Published 2021. Accessed May 3, 2023. https:\/\/www.samhsa.gov\/data\/"},{"key":"joi230114r3","unstructured":"Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health, detailed tables. Accessed July 25, 2022. https:\/\/www.samhsa.gov\/data\/report\/2020-nsduh-detailed-tables"},{"key":"joi230114r4","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2021 National Survey on Drug Use and Health. Published 2022. Accessed May 3, 2023. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt39443\/2021NSDUHFFRRev010323.pdf"},{"key":"joi230114r5","unstructured":"Jonas? DE, Amick? HR, Feltner? C, . Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings. Published May 13, 2014. Accessed May 3, 2023. https:\/\/effectivehealthcare.ahrq.gov\/products\/alcohol-misuse-drug-therapy\/research"},{"key":"joi230114r8","unstructured":"Methods guide for effectiveness and comparative effectiveness reviews. Accessed May 3, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK47095\/"},{"key":"joi230114r9","unstructured":"Viswanathan? M, Ansari? MT, Berkman? ND, . Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Published 2012. Accessed May 3, 2023. https:\/\/www.effectivehealthcare.ahrq.gov\/"},{"key":"joi230114r16","unstructured":"ClinicalTrials.gov. ALK21-014: efficacy and safety of Medisorb naltrexone (Vivitrol) after enforced abstinence. Accessed October 6, 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT00501631"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2811435\/jama_mcpheeters_2023_oi_230114_1698789093.83672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T11:41:48Z","timestamp":1699357308000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2811435"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":80,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,11,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.19761","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,7]]}}}